

HaemaLogiX is a clinical stage Australian biotech company, developing next generation immunotherapies.

Multiple myeloma is the world's second largest blood cancer with 188,000 new cases a year.

The company is sharply focused on developing highly effective drugs for the US\$25.8 billion (growing 8% p.a.) multiple myeloma market.


KEY DETAILS

Sector	Biotechnology
Headquarters	Sydney, Australia
Near-term Company Priorities	Phase 2b trial in multiple myeloma Drug development in CAR T and bispecific and trispecific drug candidates
Board	Dr Chris Baldwin, CEO & Managing Director Dr Rosanne Dunn, CSO & Director Dr John Cullity, Non-Executive Chair Alan Liddle, Non-Executive Director Dr Larry Turka, Non-Executive Director Dr Geoff Nichol, Non-Executive Director Bryce Carmine, Non-Executive Director

About Multiple Myeloma

- Forms in a type of immune system cell, known as “plasma cells”, located within the bone marrow
- Plasma cells produce the antibodies that protect the body from infections
- Most treatments for multiple myeloma damage healthy immune cells

Adverse Effects of Treatments on Patients²




Key statistics

- ~188,000 new cases per year worldwide¹
- ~543,000 living with the disease worldwide¹
- 42% of patients die within five years¹
- US\$25+ billion global annual market growing at over 8% per annum

Compelling previous clinical trial results

Response rate in Phase 2b (10 mg/kg) trial¹
Population proportion, %



KappaMab™ was highly effective in patients whose disease was progressing, even after treatments with industry leading drugs:


- **46% reduction** in the risk of death vs. matched case controls
- Two patients **remained on treatment** for over three years
- **No injury** by KappaMab™ to the patients' immune systems was observed

Why HaemaLogiX?


- Excellent safety profile, clinically validated**
Therapies designed to destroy cancerous plasma cells without on-target, off-tumour toxicity or damage to normal plasma cells
- Targeted approach to kill cancer cells**
KappaMab™/ KMCAR™ uniquely target novel antigen KMA found on cancerous plasma cells in 70% of multiple myeloma patients
- Preserves immune system and infection fighting**
Unlike current therapies, HaemaLogiX's products uniquely preserve the patient's immune system, helping to fight the cancer and maintain resistance to life-threatening infections during treatment
- Upcoming clinical trials with major inflection points**
Two separate clinical trials will provide major insights into the treatment of multiple myeloma within two years, creating the opportunity to progress to a global Phase 3 trial
- Commercial ready: manufacturing, IP**
HaemaLogiX works with world-class GMP manufacturers, including Peter Mac and Lonza, with immediate ability to upscale. Robust IP portfolio with 40+ patents granted across 10 patent families and broad geographic coverage.
- Experienced Board and Management**
Team brings decades of global biotech, pharmaceutical and capital markets experience, with proven track record in advancing novel therapies from discovery to exit or market
- Globally-recognised Scientific Advisory Board (SAB)**
Guided by a globally renowned SAB, comprising leading drug developers, who play an active role in shaping the company's clinical development and regulatory strategy

MARKET OPPORTUNITY

The global multiple myeloma market is large (US\$25.8b) and dominated by immunotherapies



Following the success of KappaMab™ at a lower dose (10mg/kg), two separate clinical studies will commence in mid-2026 with interim readouts in 2027 and full readouts in 2028. A number of significant additional milestones and inflection points are expected through the period, via the pre-clinical and clinical development programs.



For more information, please contact:

Dr Chris Baldwin
 CEO & Managing Director
chris@haemalogix.com

Or visit: www.haemalogix.com

Sources

- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2024; 74(3): 229-263., EvaluatePharma, accessed February 2026.
- IMWG 2020; CDC United States Cancer Statistics, accessed May 2020. Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race / ethnicity. Blood. 2015;125(2):410-412 ASCO (via cancer.net May 2020).

Disclaimer

This document has been prepared by HaemaLogiX Ltd ACN 603 314 496 (HaemaLogiX) primarily for general information and is dated March 2026. This document does not constitute an offer, invitation or recommendation to buy any securities outside Australia, including in the United States or to any person that is, or is acting for the account or benefit of a 'U.S. person' (as defined in Regulation S of the United States Securities Act 1993).

This document is not a prospectus or disclosure document under Australian law and does not constitute financial product or investment advice or an offer or invitation or recommendation to subscribe for or purchase securities.

This document does not purport to contain all the information required to evaluate a potential investment in HaemaLogiX and does not take into account the investment objectives, financial situation or needs of any particular investor. You should conduct your own independent review, investigation and analysis, with or without professional advice, before making an investment decision.

This document has been prepared in good faith & with due care but cannot be relied on by recipients in any way. None of HaemaLogiX or their respective directors, employees or

advisers warrant or represent, express or implied, the accuracy, correctness or completeness of the information contained in this document. To the maximum extent permitted by law, HaemaLogiX & their respective directors, employees & advisers disclaim all responsibility & liability for any loss or damage that may be incurred by any recipient relying on or using the information in this document whether that loss or damage is caused by any fault or negligence on the part of HaemaLogiX or any of their directors, employees or advisers, or otherwise.

To the extent that the document contains any forecasts, projections or other forward-looking statements, those statements involve known & unknown risks, uncertainties & other factors, some of which are beyond the control of HaemaLogiX, that may cause actual results, performance or achievements to be materially different from those expressed or implied by those statements. Neither HaemaLogiX, nor any other person, gives any redocument, warranty, assurance or guarantee that actual results, performance or achievements will be as expressed or implied in this document.

Statements made in this document are made only as at the date of this document. The information in this document remains subject to change without notice.